M&T Bank Corp Arvinas, Inc. Transaction History

M&T Bank Corp

$28.6 Billion
Q1 2024

A detailed history of M&T Bank Corp transactions in Arvinas, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 15,874 shares of ARVN stock, worth $422,565. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,874

Previous 19,161 17.15%

Holding current value

$422,565

Previous $788,000 16.88%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$36.38 - $52.31 $119,581 - $171,942	-3,287 Reduced 17.15%	15,874 $655,000
Q4 2023 Feb 06, 2024	SELL	$14.19 - $42.33 $112,413 - $335,338	-7,922 Reduced 29.25%	19,161 $788,000
Q3 2023 Nov 02, 2023	BUY	$19.64 - $28.21 $88,929 - $127,734	4,528 Added 20.08%	27,083 $531,000
Q2 2023 Aug 09, 2023	BUY	$21.73 - $31.43 $105,586 - $152,718	4,859 Added 27.46%	22,555 $559,000
Q1 2023 May 11, 2023	BUY	$26.15 - $37.26 $107,476 - $153,138	4,110 Added 30.25%	17,696 $483,000

Q4 2022 Feb 13, 2023	BUY	$32.47 - $57.24 $70,394 - $124,096	2,168 Added 22.62%	11,754 $402,000
Q4 2022 Feb 13, 2023	BUY	$32.47 - $57.24 $59,485 - $104,863	1,832 Added 15.59%	13,586 $464,000
Q3 2022 Nov 14, 2022	SELL	$41.87 - $57.99 $40,781 - $56,482	-974 Reduced 9.22%	9,586 $426,000
Q2 2022 Aug 05, 2022	BUY	$36.01 - $74.24 $86,351 - $178,027	2,398 Added 29.38%	10,560 $444,000
Q1 2022 May 09, 2022	BUY	$60.27 - $81.57 $245,961 - $332,887	4,081 Added 100.0%	8,162 $550,000
Q1 2021 May 06, 2021	SELL	$58.19 - $91.37 $46,261 - $72,639	-795 Reduced 16.3%	4,081 $270,000
Q4 2020 Feb 12, 2021	BUY	$20.19 - $84.93 $98,446 - $414,118	4,876 New	4,876 $414,000

Others Institutions Holding ARVN

# of Institutions

234

Shares Held

64.9M

Call Options Held

119K

Put Options Held

94.2K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.42B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account